Pharmacokinetics.

Slides:



Advertisements
Similar presentations
Pages 645 to 724 Mechanisms of Drug Interaction Pharmacokinetic –Reduced rate and/or completeness of absorption –Altered bioavailabilty –Reduced.
Advertisements

Clinical Pharmacokinetics
Dosage Regimen Design in Patients with Renal Insufficiency Cont’d Pharmacy 732 Winter, 2001.
Pharmacokinetics of Drug Absorption
Nonlinear pharmacokinetics
One-compartment open model: Intravenous bolus administration
Week 3 - Biopharmaceutics and Pharmacokinetics
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 25 Drug Interactions.
Laplace transformation
Practical Pharmacokinetics
Practical Pharmacokinetics September 11, 2007 Frank F. Vincenzi.
Pharmacokinetics Based on the hypothesis that the action of a drug requires presence of a certain concentration in the fluid bathing the target tissue.
Dose Adjustment in Renal and Hepatic Disease
Bioavailability of Drugs with Nonlinear Pharmacokinetics (PK) Can be Approximated by the Ratio of Doses that Provide Equal Areas under the Concentration-Time.
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
Quantitative Pharmacokinetics
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
PHARMACOKINETICS 1. Fate of drugs in the body 1.1 absorption
Nonlinear Pharmacokinetics
Pharmacokinetics Introduction
Non-linear Pharmacokinetics Arthur G. Roberts. Linear Pharmacokinetics AUC dose K Cl dose [Drug] plasma time ln[Drug] plasma time Increasing Dose.
1 Applied Pharmacokinetics of Antiepileptic Drugs (AEDs) B. Gitanjali Gitanjali-21:
PHARMACOKINETIC MODELS
MECHANISTIC PHARMACOKINETICS: COMPARTMENTAL MODELS
The General Concepts of Pharmacokinetics and Pharmacodynamics
1. Fate of drugs in the body 1.1 absorption 1.2 distribution - volume of distribution 1.3 elimination - clearance 2. The half-life and its uses 3. Repeated.
Continuous intravenous infusion (one-compartment model)
Quantitative Pharmacokinetics
Plasma Protein Binding
PHARMACOKINETICS Definition: quantitative study of drug absorption, distribution, metabolism, and excretion (ADME), and their mathematical relationship.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
Grading Average = 91. Errata Michaelis-Menten Derivation KmKm k cat Formation of ES complex is rapid (k cat
The General Concepts of Pharmacokinetics and Pharmacodynamics
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics.
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics Tutoring
Chapter 7 COMPARTMENT MODELS
Lecture-8 Biopharmaceutics
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics.
PHARMACOKINETICS Allie punke
Controls and Functions
Pharmacokinetics.
Pharmacokinetics Tutoring
Dosing Regimen Concepts: 2-C, MM, Individualization principles
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
Pharmacokinetics.
Anticonvulsants: Valproic acid
Pharmacokinetics.
Pharmcokinetics Allie punke.
Pharmcokinetics Allie punke.
Pharmacokinetics.
Therapeutic Drug Monitoring
Hawler Medical University
Linear vs Non-linear System
Therapeutic Drug Monitoring chapter 1 part 1
Clinical Pharmacokinetics
Pharmacokinetics lecture 12 Contents ...
Q1: Drug A is a small and hydrophilic compound that distributes to extracellular fluids only. It has a volume of distribution of 5.6 L in a healthy 70-kg.
Therapeutic Drug Monitoring
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
Objectives To discuss what happens after drug administration
A change in either volume of distribution or clearance has differing effects on the concentration-time profile. A change in either volume of distribution.
Presentation transcript:

Pharmacokinetics

Volumes and protein binding

Volumes and protein binding Which of the following alteration in protein binding is likely to be the most clinically significant acutely? A. Volume of distribution=2, fut is increased B. Volume of distribution=150, fut is decreased C. Volume of distribution=2, fut is decreased D. Volume of distribution=150, fup is increased B. Protein displacement is only relevent if the unbound Vd (Vu) is significantly decreased. This is only relevant for drugs with small volume of distribution that are displaced from plasma protein binding OR for drugs with Large Vd where displacement occurs from tissue binding sites.

Volumes and protein binding If fup is increased, which of the following situations would most likely require a change in MD? A. Low E drug IV B. Low E drug PO C. High E drug IV D. High E drug PO Only C. This is really the only concern!

Volumes and protein binding When do you see a “spike” on the time vs concentration graph (aka transient increase) when fup is increased? A. Both PO and IV Low E drugs B. High E drug given IV C. Only Low E drug given IV D. High E drug given PO E. Both A and D This happens because the increase in fup causes a decrease in total Css, but no change in Css,u (takes a little time to go back to normal). This acute change also ONLY occurs if the drug has a low Vd. Also, for high E PO, fup’s also cancel out.

Volumes and protein binding When are you likely to see a clinically significant effect if fup is changed? Low or High protein binding? Wide or narrow therapeutic index? High or Low E drug? IV or PO? Know this chart!!

Volumes and protein binding Which of the following would result in the most clinically significant (concerning) situation? A. Nonlinear elimination B. Nonlinear plasma protein binding C. Both D. Neither A, because if you double dose, increase Css more than double b/c decreased Clint. B would result in increased CL, so you’d get less than doubling.

Volumes and protein binding Describe the phases of nonlinear protein binding: A= low concentrations. Constant fup. Doesn’t change. Most drugs. B= increase Cu now increase fup (for a drug that binds to a saturable protein). Few drugs C= Toxic range. Higher concentration because protein is now saturated

Dose dependence

Dose dependence CL,T=300 ml/min, fe=0.1. If this drug exhibits non-linear pharmacokinetics, what will be affected causing an increase in AUC? A. Because it is a high extraction drug, the CL will be affected B. Because it is a low extraction drug, the CL will be affected C. Because it is a high extraction drug, the F will be affected D. Because it is a low extraction drug, the F will be affected. B CL (low e drugs)= fup*CLint

Dose dependence High Extraction Drugs Low Extraction Drugs CL= F*= Non-linear PK manifests in: Terminal slope will be: Half life: CL= F*= Non-linear PK manifests in: Terminal slope will be: Half-life: High non-linear Pk affects F, while for low E drugs, non-linear PK affects CL *Terminal slope for high E drugs will be the same, since CL=k*V…not affecting CL, only affecting F.

Dose dependence

Dose dependence

Dose dependence

Questions?